JP2019533715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533715A5 JP2019533715A5 JP2019525021A JP2019525021A JP2019533715A5 JP 2019533715 A5 JP2019533715 A5 JP 2019533715A5 JP 2019525021 A JP2019525021 A JP 2019525021A JP 2019525021 A JP2019525021 A JP 2019525021A JP 2019533715 A5 JP2019533715 A5 JP 2019533715A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- ldl
- pcsk9
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 37
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 108010028554 LDL Cholesterol Proteins 0.000 claims 32
- 239000003814 drug Substances 0.000 claims 22
- 229940124597 therapeutic agent Drugs 0.000 claims 22
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 18
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 12
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 11
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 10
- 206010003210 Arteriosclerosis Diseases 0.000 claims 8
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 8
- 208000029078 coronary artery disease Diseases 0.000 claims 8
- 208000026758 coronary atherosclerosis Diseases 0.000 claims 8
- 230000003472 neutralizing effect Effects 0.000 claims 8
- 230000007211 cardiovascular event Effects 0.000 claims 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 3
- 229960002027 evolocumab Drugs 0.000 claims 3
- 206010061818 Disease progression Diseases 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 102000053786 human PCSK9 Human genes 0.000 claims 2
- 231100000518 lethal Toxicity 0.000 claims 2
- 230000001665 lethal effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000000250 revascularization Effects 0.000 claims 2
- 230000006441 vascular event Effects 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 235000009421 Myristica fragrans Nutrition 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 239000001115 mace Substances 0.000 claims 1
- 231100001160 nonlethal Toxicity 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023019926A JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662421685P | 2016-11-14 | 2016-11-14 | |
| US62/421,685 | 2016-11-14 | ||
| US201762471874P | 2017-03-15 | 2017-03-15 | |
| US62/471,874 | 2017-03-15 | ||
| US201762515117P | 2017-06-05 | 2017-06-05 | |
| US62/515,117 | 2017-06-05 | ||
| US201762581244P | 2017-11-03 | 2017-11-03 | |
| US62/581,244 | 2017-11-03 | ||
| US201762584600P | 2017-11-10 | 2017-11-10 | |
| US62/584,600 | 2017-11-10 | ||
| PCT/US2017/061346 WO2018089912A2 (en) | 2016-11-14 | 2017-11-13 | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019926A Division JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533715A JP2019533715A (ja) | 2019-11-21 |
| JP2019533715A5 true JP2019533715A5 (OSRAM) | 2020-12-24 |
Family
ID=60484496
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019525021A Pending JP2019533715A (ja) | 2016-11-14 | 2017-11-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2023019926A Pending JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A Pending JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019926A Pending JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A Pending JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200368350A1 (OSRAM) |
| EP (1) | EP3538149A2 (OSRAM) |
| JP (3) | JP2019533715A (OSRAM) |
| KR (2) | KR20190085963A (OSRAM) |
| CN (1) | CN110234350A (OSRAM) |
| AU (2) | AU2017356219A1 (OSRAM) |
| BR (1) | BR112019009726A2 (OSRAM) |
| CA (1) | CA3043700A1 (OSRAM) |
| CL (2) | CL2019001304A1 (OSRAM) |
| CO (1) | CO2019004814A2 (OSRAM) |
| IL (1) | IL266579A (OSRAM) |
| JO (1) | JOP20190112A1 (OSRAM) |
| MA (1) | MA46758A (OSRAM) |
| MX (3) | MX2019005627A (OSRAM) |
| TN (1) | TN2019000156A1 (OSRAM) |
| WO (1) | WO2018089912A2 (OSRAM) |
| ZA (1) | ZA201902975B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016010927A1 (en) * | 2014-07-14 | 2016-01-21 | Amgen Inc. | Crystalline antibody formulations |
| JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| JP2021533190A (ja) * | 2018-07-31 | 2021-12-02 | タン ウェンTAN, Wen | ＬＤＬコレステロールの細胞内クリアランスを増強しかつスタチンとの併用療法で効力を高めかつ副作用を減らすための、カルバメートβフェニルエタノールアミン類似体の新規使用法 |
| US20220245219A1 (en) * | 2019-07-19 | 2022-08-04 | Ebay Inc. | Sample Delta Monitoring |
| CN112656792B (zh) * | 2021-01-26 | 2022-07-05 | 首都医科大学宣武医院 | 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103614375A (zh) | 2006-05-11 | 2014-03-05 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Ｐｃｓｋ９拮抗劑類 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| WO2010078536A1 (en) * | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| EA201270019A1 (ru) | 2009-06-15 | 2012-06-29 | Элнилэм Фармасьютикалз, Инк. | Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9 |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| SG191219A1 (en) | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
| KR20140006022A (ko) | 2011-02-11 | 2014-01-15 | 아이알엠 엘엘씨 | Pcsk9 길항제 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| MX388989B (es) * | 2015-01-09 | 2025-03-11 | Global Genomics Group Llc | Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica. |
| EA039310B1 (ru) * | 2015-02-26 | 2022-01-12 | Санофи Байотекнолоджи | Способы снижения сердечно-сосудистого риска |
-
2017
- 2017-06-16 JO JOP/2019/0112A patent/JOP20190112A1/ar unknown
- 2017-11-13 BR BR112019009726A patent/BR112019009726A2/pt unknown
- 2017-11-13 AU AU2017356219A patent/AU2017356219A1/en not_active Abandoned
- 2017-11-13 CA CA3043700A patent/CA3043700A1/en active Pending
- 2017-11-13 MX MX2019005627A patent/MX2019005627A/es unknown
- 2017-11-13 WO PCT/US2017/061346 patent/WO2018089912A2/en not_active Ceased
- 2017-11-13 JP JP2019525021A patent/JP2019533715A/ja active Pending
- 2017-11-13 EP EP17805364.1A patent/EP3538149A2/en active Pending
- 2017-11-13 CN CN201780083280.9A patent/CN110234350A/zh active Pending
- 2017-11-13 KR KR1020197016872A patent/KR20190085963A/ko not_active Ceased
- 2017-11-13 KR KR1020247018411A patent/KR20240096648A/ko active Pending
- 2017-11-13 TN TNP/2019/000156A patent/TN2019000156A1/en unknown
- 2017-11-13 US US16/348,653 patent/US20200368350A1/en active Pending
- 2017-11-13 MA MA046758A patent/MA46758A/fr unknown
-
2019
- 2019-05-12 IL IL266579A patent/IL266579A/en unknown
- 2019-05-13 ZA ZA2019/02975A patent/ZA201902975B/en unknown
- 2019-05-13 CO CONC2019/0004814A patent/CO2019004814A2/es unknown
- 2019-05-13 CL CL2019001304A patent/CL2019001304A1/es unknown
- 2019-05-14 MX MX2025002106A patent/MX2025002106A/es unknown
- 2019-05-14 MX MX2024000805A patent/MX2024000805A/es unknown
-
2020
- 2020-11-18 CL CL2020002993A patent/CL2020002993A1/es unknown
-
2023
- 2023-02-13 JP JP2023019926A patent/JP2023071715A/ja active Pending
-
2024
- 2024-12-06 AU AU2024278180A patent/AU2024278180A1/en active Pending
-
2025
- 2025-03-04 JP JP2025033900A patent/JP2025102770A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533715A5 (OSRAM) | ||
| Keene et al. | Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients | |
| Ong et al. | An evidence-based update on nonsteroidal anti-inflammatory drugs | |
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| Abraham et al. | Optimal management of digital ulcers in systemic sclerosis | |
| NO20073456L (no) | Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| IL300151A (en) | Combinations for the treatment of cancer | |
| JP2017506626A5 (OSRAM) | ||
| JP2017528427A5 (OSRAM) | ||
| WO2006037031A3 (en) | Formulations and methods for treatment of inflammatory diseases | |
| JP2015518897A5 (OSRAM) | ||
| Simon et al. | Treatment of hypertensive and hypercholesterolaemic patients with the triple fixed combination of atorvastatin, perindopril and amlodipine: the results of the CORAL study | |
| KR20160043117A (ko) | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 | |
| Bertrand et al. | Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine | |
| Constance et al. | Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects≥ 65 years | |
| Gertner | Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome | |
| US9713608B2 (en) | Method for topically treating actinic keratosis on the trunk (except chest) or extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate) | |
| Amuchastegui et al. | Disulfiram--alcohol reaction mimicking an acute coronary syndrome. | |
| Teixeira | Scientific basis of the homeopathic healing principle in modern pharmacology | |
| JP2018516931A5 (OSRAM) | ||
| WO2008121461A3 (en) | Vaccine for activating helper function of cd8+ tcells | |
| JPWO2006104086A1 (ja) | 血栓症治療剤 |